CHRNA4 (Cholinergic Receptor Nicotinic Alpha 4 Subunit) is a Protein Coding gene. Diseases associated with CHRNA4 include Epilepsy, Nocturnal Frontal Lobe, 1 and Autosomal Dominant Nocturnal Frontal Lobe Epilepsy. Among its related pathways are Nanog in Mammalian ESC Pluripotency and Acetylcholine Binding And Downstream Events. CHRNA4 encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000 ELISA 1:5000-20000.

ACHA4 Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Find more details at https://www.abbkine.com/product/acha4-polyclonal-antibody-abp57676/

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.